Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1

Melanoma is the most dangerous type of skin cancer accounting for 48,000 deaths worldwide each year and an average survival rate of about 6-10 months with conventional treatment. Tumor metastasis and chemoresistance of melanoma cells are reported as the main reasons for the insufficiency of currentl...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 3; p. e0119402
Main Authors Kreiseder, Birgit, Holper-Schichl, Yvonne M, Muellauer, Barbara, Jacobi, Nico, Pretsch, Alexander, Schmid, Johannes A, de Martin, Rainer, Hundsberger, Harald, Eger, Andreas, Wiesner, Christoph
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 20.03.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Melanoma is the most dangerous type of skin cancer accounting for 48,000 deaths worldwide each year and an average survival rate of about 6-10 months with conventional treatment. Tumor metastasis and chemoresistance of melanoma cells are reported as the main reasons for the insufficiency of currently available treatments for late stage melanoma. The cytoskeletal linker protein α-catulin (CTNNAL1) has been shown to be important in inflammation, apoptosis and cytoskeletal reorganization. Recently, we found an elevated expression of α-catulin in melanoma cells. Ectopic expression of α-catulin promoted melanoma progression and occurred concomitantly with the downregulation of E-cadherin and the upregulation of mesenchymal genes such as N-cadherin, Snail/Slug and the matrix metalloproteinases 2 and 9. In the current study we showed that α-catulin knockdown reduced NF-κB and AP-1 activity in malignant melanoma cells. Further, downregulation of α-catulin diminished ERK phosphorylation in malignant melanoma cells and sensitized them to treatment with chemotherapeutic drugs. In particular, cisplatin treatment led to decreased ERK-, JNK- and c-Jun phosphorylation in α-catulin knockdown melanoma cells, which was accompanied by enhanced apoptosis compared to control cells. Altogether, these results suggest that targeted inhibition of α-catulin may be used as a viable therapeutic strategy to chemosensitize melanoma cells to cisplatin by down-regulation of NF-κB and MAPK pathways.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: CW AE HH JAS RdM. Performed the experiments: BK YMHS BM NJ CW. Analyzed the data: CW AE BK. Contributed reagents/materials/analysis tools: AP RdM HH. Wrote the paper: CW BK JAS RdM.
Competing Interests: There exists no competing interests and there is no financial intent to market the results of this manuscript somehow. Most of the results were produced at the University of Applied Sciences in Krems, Austria where the first author (B. Kreiseder) was employed before she changed to SeaLife Pharma GmbH. The last author (C. Wiesner) is employed at the University in Krems and at SeaLife Pharma GmbH. Just very few results were produced at SeaLife Pharma mainly to finalize the manuscript. The research of SeaLife Pharma GmbH focuses on the production (isolation) of anti-infective molecules such as Anthraquinone-Derivatives for the treatment of MRSA. There is no interest in cancer research. Up to now, SeaLife Pharma has no products on the market. On behalf of all authors, I declare that there are no competing interests for the purposes of transparency. We confirm that this does not alter our adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0119402